Company

CorriXR Therapeutics

Biotechnology Research 550 S College Ave 5 employees

Employees: 5
Contacts: 4
Emails: 4
Phones: 3

corrixr.com LinkedIn Crunchbase

CorriXR Therapeutics Overview

Headquarters: 550 S College Ave
Website: corrixr.com
Industry: Biotechnology Research
Employees: 5
Founded: 2022
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

Kazia Therapeutics Limited

About CorriXR Therapeutics

CorriXR Therapeutics is on the clinical frontier of gene editing as a transformative pre-clinical stage biotechnology company with a ground-breaking in vivo gene editing therapeutic platform technology. CorriXR Therapeutics advances CRISPR/Cas gene editing technology to develop new genetic medicines directed against drug-resistant solid tumors.

CorriXR Therapeutics Contact Details

People in AeroLeads: 4
With contact data: 4
Email contacts: 4; 100.0% coverage
Phone contacts: 3; 75.0% coverage

CorriXR Therapeutics Org Chart

Sample employees and titles

Name	Title	Location	Contact
Jennifer Kmiec	Chief of Staff, Corrixr Therapeutics	Greater Philadelphia, United States	Email Phone
Eric B. Kmiec	Executive Director & Chief Scientific	Newark, Delaware, United States	Email Phone
Jeffrey A. Carper	Board Member at Gentas Biotechnology	Wilmington, Delaware, United States	Email Phone
Gregory T.	Chief of Surgical Oncology : Southern	Greater Philadelphia, United States	Email